Author

admin

Browsing

A gunman opened fire at an adult education center in the Swedish city of Örebro on Tuesday, killing at least 10 people in what the country’s prime minister called the “worst mass shooting in Swedish history.”

Swedish police are still piecing together how the tragedy occurred. Here’s what we know so far.

What happened?

At 12:33 p.m. local time (6:33 a.m. ET) on Tuesday, police received reports of a shooting in Örebro, a city about 160 kilometers (100 miles) west of the capital, Stockholm.

The shooting occurred at Campus Risbergska, a school for adults who have not completed earlier stages of education. Such facilities are known as a Komvux in Sweden. Komvuxes provide vocational training, Swedish language classes and other courses for adults seeking the qualifications needed to gain employment. They are also essential services for Sweden’s refugee and migrant populations.

Cellphone videos showed students taking shelter under desks while alarms screeched and red lights flashed.

He said his classmates barricaded the doors and took cover for around an hour, before police entered the classroom and evacuated the students. “There was blood all over the corridor,” Sundling said.

How many people were killed or injured?

At least 10 people were killed and six were injured in the attack, police said. The attacker also died.

In an update Wednesday, Örebro regional authorities said six people were being treated at the local university hospital.

Three women and two men, all adults, were admitted for gunshot wounds and underwent surgery. Initially thought to have life-threatening injuries, the authorities said the five are now in a “stable but serious” condition.

Another woman also received treatment for more minor injuries. No one else was admitted to the hospital overnight, authorities said.

By the time the attack began, many students had left the campus after taking a national exam on Tuesday, Lena Warenmark, a teacher, told Swedish public broadcaster SVT.

Mary Pegado, a 54-year-old teacher at the school, said she and her students had run to safety after someone burst into her classroom and told them to get out.

“I think of my students,” Pegado told Reuters. “Many of them have fled from countries where things like this happen, and now they experience it here. It is horrible,” she said.

What do we know about the perpetrator?

Not much, yet. Police said that the attacker was not known to them, that he was not connected to any gangs and that he was not believed to be acting based on ideological motives.

“At the moment, the police believe that the perpetrator was acting alone, but we cannot rule out more perpetrators connected to the incident,” police said Tuesday. They also did not say what type of weapon the perpetrator used.

Police said that the attacker also shot at officers after they arrived at the campus. In a press conference Wednesday, police said that when they found the attacker, he was already dead and that it appears that he shot himself. The attacker has not yet been identified by authorities.

How rare are attacks like these?

School shootings are rare, but Sweden – long associated with high living standards and a strong social safety net – has seen a surge in violent crime in recent years, driven in part by gang warfare.

In 2023, Sweden had the highest rate of deadly gun violence per capita in the European Union, according to Reuters. In 2024, at least 40 people were shot dead in the country of only 10 million people – down from a peak of 63 people shot dead in 2022.

Although Sweden has high rates of gun ownership by EU standards, Swedes have to obtain a license before being allowed to own a weapon and the country places tight restrictions on eligibility.

Prime Minister Kristersson called for an investigation into how Tuesday’s “horrific” crime could have occurred.

“We’ve today seen brutal, deadly violence against completely innocent people – this is the worst mass shooting in Swedish history,” he said.

This post appeared first on cnn.com

Despite Democrats’ attempts to slow down the process to approve President Donald Trump’s picks for various administration positions, the Republican-led Senate is confirming nominees at a record pace.

The Senate Republicans Communication Center reported on Tuesday that under the leadership of Sen. John Thune, R-S.D., confirmations are moving quicker than they did during the Biden administration and Trump’s first term.

As of Feb. 4, the previous two administrations – former President Joe Biden’s and Trump’s first term – only had six nominees confirmed, while the current administration has 11 positions officially filled.

On Tuesday, Trump’s pick for attorney general in Pam Bondi was confirmed, as was Doug Collins for secretary of veterans affairs.

Tulsi Gabbard, selected for director of national intelligence, and Robert F. Kennedy, Jr., chosen to lead the department of health and human services, are next up for their confirmation votes after making it out of committee hearings on Tuesday.

After Gabbard and RFK Jr., nine more nominees await confirmation.

Sen. Markwayne Mullin, R-Okla., shared a roundup on X of where confirmations stand as of Tuesday night.

A handful of Republican senators chimed in on the pace and promised to keep it up until all nominees are confirmed.

‘.@SenateGOP is delivering results. Despite Democrat obstruction, we’re confirming @POTUS’ nominees at a strong pace—faster than in the Biden admin or first Trump admin. I’ll keep fighting to confirm President Trump’s team,’ Sen. Katie Britt, R-Ala., wrote on X.

Sen. Steve Daines, R-Mon., said the chamber is ‘ahead of schedule and not slowing down.’

The last administration to have all nominees quickly confirmed was former President George W. Bush, whose entire Cabinet was in place by Feb. 1, according to PresidentialTransition.org.

Trump’s first term saw all picks confirmed by the end of April, a timeline similar to former President Barack Obama’s, while Biden’s Cabinet was filled by March 22.

This post appeared first on FOX NEWS

NEWYou can now listen to Fox News articles!

President Donald Trump achieved a vision of peace and prosperity in the Middle East none thought possible in his first term. Now, he has an incredible opportunity to reshape the future of the Middle East for years to come. 

This week, he took the first step toward realizing this vision by doubling down on his maximum pressure campaign against Iran. His team can complement this sanctions approach by continuing the work of the first Trump administration and expanding the Abraham Accords. 

As the past four years have shown, enriching and enabling the malign Iranian regime only leads to war and terror. As Trump demonstrated, the best way to avoid these outcomes is through massive and effective sanctions on Iranian oil exports, which allow the regime to prop up its dysfunctional economy, fund terrorist proxies like Hamas and Hezbollah, and inflict pain and suffering on the Iranian people.

This is why we in the first Trump administration, at the president’s direction, successfully targeted Iran’s oil exports with historic sanctions. At the end of our tenure, Iran’s oil exports had fallen to just about 400,000 barrels a day. Like an animal caught in a trap, the regime thrashed and tried to break free by escalating tensions and instigating conflict. 

President Trump met this escalation with steel resolve in the form of contained, lethal strikes – like that which claimed the life of Quds Force commander Qasem Soleimani – that maintained deterrence while not putting American soldiers in harm’s way. 

By bankrupting the Iranian regime and building a coalition of partners and allies willing to contain Iran through the Abraham Accords, the first Trump administration laid the groundwork for a genuinely peaceful and prosperous Middle East. I was proud to have contributed to this historic effort as secretary of state. 

Unfortunately, the Biden administration favored appeasement rather than deterrence. It failed to continue our sanctions program, made obscene ransom payments to the ayatollah, and revived the Obama-era falsehood that the regime would moderate – if only the right deal could be struck. 

Led astray by fantasy, Obama’s successors in Team Biden went right back to enriching the regime at the expense of America’s security and that of our allies. At one point in the administration, Iran was exporting roughly 2 million barrels of oil per day – five times more than it had been just a few years prior – and Iran sold $144 billion worth of oil over Team Biden’s first three years.

This infusion of wealth yielded predictable results. Iran resumed funding its proxies, Hamas perpetrated its grotesque attacks on Oct. 7, 2023, and the Houthis initiated a blockade of the Red Sea that lasted more than a year. Iranian-backed militias killed six American service members over the administration’s last two years in office. Iran built and sold thousands of drones to Russia that bolstered Vladimir Putin’s invasion of Ukraine, and it sold more oil than ever to the People’s Republic of China. 

Abandoning our maximum pressure campaign was a disaster for America’s foreign policy and national security. 

President Trump’s decision to reverse Biden’s appeasement and bring back our maximum pressure campaign was necessary, and its timing is perfect: Israel’s incapacitation of Hezbollah helped lead to the downfall of Bashar al-Assad in Syria, and Israel’s campaign in Gaza to destroy Hamas is nearing victory.  

These realities have left the regime in Tehran at its weakest point in years. Now is the time not only for maximum pressure to return with support for the organized opposition within Iran, but also for the White House to fully support our ally Israel in its mission to ensure Iran never reaches its goal of creating a nuclear weapon.

This will set the stage for the Iranian people to decide their own future instead of the tyrannical despots in Tehran, and it will give our partners and allies in the region the space and security they need to deepen their economic and security ties.

Whether within Iran, across the Middle East, or elsewhere, the return of President Trump’s maximum pressure campaign is tremendous news for lovers of liberty – but his team should not stop there. 

Iran is not our only vulnerable adversary: Putin’s wartime economy is on life support, and the Chinese Communist Party’s centrally-planned economy is under serious strain. Now is not the time to back off, relieve pressure or seek deals – now is the time to secure a better future for the United States and the world. 

President Trump’s maximum pressure campaign worked once against Iran, and it will work again; he should expand this strategy beyond the regime in Tehran.

This post appeared first on FOX NEWS

Earnings season is in full swing in the pharma sector with major players sharing their latest results.

On Tuesday (February 4), Amgen (NASDAQ:AMGN), Merck (NYSE:MRK) and Pfizer (NYSE:PFE) released financial results for the most recent quarter, providing critical data points for evaluating investment potential.

Amgen reports strong Q4, will focus on trials in 2025

Amgen’s financial results for Q4 and the full 2024 year reveal quarterly revenue of over US$9 billion, beating analysts’ estimates of US$8.87 billion. Revenue for the year came in at US$33.42 billion, ahead of projections of US$33.19 billion, driven by an overall increase in the volume of demand for its products.

An 11 percent year-on-year increase in product sales was primarily by the pharmaceutical company’s strong performance in oncology and immunology therapies, along with sales of Repatha, which treats high cholesterol, and Evenity, which treats osteoporosis in postmenopausal women.

Earning per share (EPS) also beat estimates of US$5.08, coming in at US$5.31.

Amgen performance, February 4, 2025.

Amgen performance, February 4, 2025.

Chart via Google Finance.

Looking ahead, Amgen’s revenue guidance for fiscal year 2025 was between US$34.3 billion and US$35.7 billion, in line with the average estimate of US$34.53 billion. Phase III trials of its weight management candidate MariTide, a dual GIP and GLP-1 receptor modulator, are expected to begin in H1 2025.

While Amgen’s shares have decreased by over ten percent year-on-year, they have increased by nearly 11 percent year-to-date. The stock closed with a marginal gain of 0.05 percent at US$289.01.

Merck beats on revenue, but Gardasil sales decline

Merck fell by nearly 11 percent ahead of the opening bell on Tuesday after its Q4 and full-year 2024 financial results showed adjusted sales revenue for its key vaccine, despite exceeding sales and profit expectations.

The company reported revenue of US$15.62 billion, beating analysts estimates of US$15.55 billion.

Earnings per share for the quarter were also ahead of expectations, US$1.72 compared to US$1.69; however, earnings per share were US$6.74 for the full year, compared to analysts’ estimates of US$7.62.

Sales reached US$15.6 billion in Q4, an increase of 7 percent from the prior year.

Full-year sales also rose by 7 percent to US$64.2 billion, driven by sales of Keytruda, the company’s leading cancer therapy. Keytruda brought in US$29.5 billion, representing an annual growth of 18 percent.

The company also announced positive topline results from a Phase 3 trial evaluating a subcutaneous formulation of pembrolizumab used in combination with Keytruda in adult patients with metastatic non-small cell lung cancer.

However, sales of Gardasil and Gardasil 9, two HPV vaccines, declined by 3 percent to US$8.6 billion.

Merck performance, February 4, 2025.

Merck performance, February 4, 2025.

Chart via Google Finance.

For its 2025 fiscal year, Merck expects full-year adjusted EPS to be between US$8.88 and US$9.03, and revenue to fall somewhere between US$64.1 billion and US$65.6 billion. Analysts had been projecting EPS of US$9.13 and revenue of US$67.07 billion. The company also withdrew its US$11 billion sales target for Gardasil by 2030.

“This sales range reflects a decision to temporarily pause shipments of GARDASIL/GARDASIL 9 into China beginning February 2025 through at least mid-year,” the company said in an accompanying statement. According to Biopharma Dive, CEO Rob Davis clarified in the firm’s earnings call that the pause will “facilitate a more rapid reduction of inventory and help support the financial position” of its Chinese distribution partner, Zhifei Biological Products.

“China still represents a significant long-term opportunity for Gardasil given the large number of females, and now males with our recent approval, that are not yet immunized,” Davis said.

Pfizer discusses Seagen acquisition impact and 2025 outlook

Pfizer’s Q4 and 2024 financial results show revenue at US$17.8 billion, an increase of 22 percent compared to the previous year and exceeding expectations of US$14.31 billion. Revenue, excluding COVID-19-related therapies, was largely driven by Seagan’s portfolio of cancer therapies following its acquisition in December 2023.

However, full-year revenue fell slightly short at US$63 billion, compared to projections of US$63.6 billion. EPS was also below analysts’ estimates of US$0.71, coming in at US$0.63.

Its share price fell by 4.3 percent in early trading and ended the day down 1.26 percent.

Pfizer performance, February 4, 2025.

Pfizer performance, February 4, 2025.

Chart via Google Finance.

Looking ahead, Pfizer will continue to focus on growing its pipeline of cancer drugs in 2025, with three potential therapies awaiting regulatory approval in 2025. The company will also initiate clinical trials for therapies related to inflammation, immunology, and internal medicine. For its 2025 fiscal year, Pfizer is projecting revenue of between US$61 billion and US$64 billion, aligning with the average estimate of US$63.22 billion.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Earnings season is in full swing in the pharma sector with major players sharing their latest results.

On Tuesday (February 4), Amgen (NASDAQ:AMGN), Merck (NYSE:MRK) and Pfizer (NYSE:PFE) released financial results for the most recent quarter, providing critical data points for evaluating investment potential.

Amgen reports strong Q4, will focus on trials in 2025

Amgen’s financial results for Q4 and the full 2024 year reveal quarterly revenue of over US$9 billion, beating analysts’ estimates of US$8.87 billion. Revenue for the year came in at US$33.42 billion, ahead of projections of US$33.19 billion, driven by an overall increase in the volume of demand for its products.

An 11 percent year-on-year increase in product sales was primarily by the pharmaceutical company’s strong performance in oncology and immunology therapies, along with sales of Repatha, which treats high cholesterol, and Evenity, which treats osteoporosis in postmenopausal women.

Earning per share (EPS) also beat estimates of US$5.08, coming in at US$5.31.

Amgen performance, February 4, 2025.

Amgen performance, February 4, 2025.

Chart via Google Finance.

Looking ahead, Amgen’s revenue guidance for fiscal year 2025 was between US$34.3 billion and US$35.7 billion, in line with the average estimate of US$34.53 billion. Phase III trials of its weight management candidate MariTide, a dual GIP and GLP-1 receptor modulator, are expected to begin in H1 2025.

While Amgen’s shares have decreased by over ten percent year-on-year, they have increased by nearly 11 percent year-to-date. The stock closed with a marginal gain of 0.05 percent at US$289.01.

Merck beats on revenue, but Gardasil sales decline

Merck fell by nearly 11 percent ahead of the opening bell on Tuesday after its Q4 and full-year 2024 financial results showed adjusted sales revenue for its key vaccine, despite exceeding sales and profit expectations.

The company reported revenue of US$15.62 billion, beating analysts estimates of US$15.55 billion.

Earnings per share for the quarter were also ahead of expectations, US$1.72 compared to US$1.69; however, earnings per share were US$6.74 for the full year, compared to analysts’ estimates of US$7.62.

Sales reached US$15.6 billion in Q4, an increase of 7 percent from the prior year.

Full-year sales also rose by 7 percent to US$64.2 billion, driven by sales of Keytruda, the company’s leading cancer therapy. Keytruda brought in US$29.5 billion, representing an annual growth of 18 percent.

The company also announced positive topline results from a Phase 3 trial evaluating a subcutaneous formulation of pembrolizumab used in combination with Keytruda in adult patients with metastatic non-small cell lung cancer.

However, sales of Gardasil and Gardasil 9, two HPV vaccines, declined by 3 percent to US$8.6 billion.

Merck performance, February 4, 2025.

Merck performance, February 4, 2025.

Chart via Google Finance.

For its 2025 fiscal year, Merck expects full-year adjusted EPS to be between US$8.88 and US$9.03, and revenue to fall somewhere between US$64.1 billion and US$65.6 billion. Analysts had been projecting EPS of US$9.13 and revenue of US$67.07 billion. The company also withdrew its US$11 billion sales target for Gardasil by 2030.

“This sales range reflects a decision to temporarily pause shipments of GARDASIL/GARDASIL 9 into China beginning February 2025 through at least mid-year,” the company said in an accompanying statement. According to Biopharma Dive, CEO Rob Davis clarified in the firm’s earnings call that the pause will “facilitate a more rapid reduction of inventory and help support the financial position” of its Chinese distribution partner, Zhifei Biological Products.

“China still represents a significant long-term opportunity for Gardasil given the large number of females, and now males with our recent approval, that are not yet immunized,” Davis said.

Pfizer discusses Seagen acquisition impact and 2025 outlook

Pfizer’s Q4 and 2024 financial results show revenue at US$17.8 billion, an increase of 22 percent compared to the previous year and exceeding expectations of US$14.31 billion. Revenue, excluding COVID-19-related therapies, was largely driven by Seagan’s portfolio of cancer therapies following its acquisition in December 2023.

However, full-year revenue fell slightly short at US$63 billion, compared to projections of US$63.6 billion. EPS was also below analysts’ estimates of US$0.71, coming in at US$0.63.

Its share price fell by 4.3 percent in early trading and ended the day down 1.26 percent.

Pfizer performance, February 4, 2025.

Pfizer performance, February 4, 2025.

Chart via Google Finance.

Looking ahead, Pfizer will continue to focus on growing its pipeline of cancer drugs in 2025, with three potential therapies awaiting regulatory approval in 2025. The company will also initiate clinical trials for therapies related to inflammation, immunology, and internal medicine. For its 2025 fiscal year, Pfizer is projecting revenue of between US$61 billion and US$64 billion, aligning with the average estimate of US$63.22 billion.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Saudi Arabia said it would not establish ties with Israel unless a Palestinian state is created, shooting down U.S. President Donald Trump’s claim that the Saudis were not demanding a Palestinian homeland when he floated the idea of the U.S. government taking control of the Gaza Strip.

Trump said on Tuesday at a joint press conference with Israeli Prime Minister Benjamin Netanyahu that he wants the U.S. to take over the Gaza Strip, which has been ravaged by the Israel-Hamas war, after Palestinians are resettled in other countries.

‘The U.S. will take over the Gaza Strip, and we will do a job with it, too,’ Trump said at the White House. ‘We’ll own it and be responsible for dismantling all of the dangerous, unexplored bombs and other weapons on the site.’

‘Level the site and get rid of the destroyed buildings, level it out, create an economic development that will supply unlimited numbers of jobs and housing for the people of the area,’ he said. ‘Do a real job. Do something different. Just can’t go back. If you go back, it’s going to end up the same way it has for 100 years.’

Saudi Arabia’s foreign ministry said in a statement on Wednesday that the country rejects any attempts to displace the Palestinians from their homeland, stressing that its position on the Palestinians is not up to negotiation.

The statement noted that Saudi Crown Prince Mohammed bin Salman has affirmed the kingdom’s position in ‘a clear and explicit manner’ that does not make other interpretations possible under any circumstances.

Any proposed displacement of Palestinians, an idea Trump has suggested multiple times since retaking office last month, is a highly sensitive matter for both Palestinians and Arab countries.

Trump said on Jan. 25 that he wanted Jordan, Egypt and other Arab nations to accept more Palestinian refugees from the Gaza Strip, potentially moving out enough people to ‘just clean out’ the area.

‘You’re talking about probably a million and a half people, and we just clean out that whole thing and say, ‘You know, it’s over,” he said at the time.

Amid the Israel-Hamas war in Gaza, Palestinians feared they would suffer from another ‘Nakba,’ meaning catastrophe in Arabic, which refers to the displacement and dispossession of hundreds of thousands of Palestinians during the 1948 war at the birth of the State of Israel.

The U.S. had led months of diplomacy to convince Saudi Arabia to normalize ties with Israel and recognize the Middle Eastern country. But the war in Gaza, which began with Hamas’ Oct. 7, 2023, attack on the Jewish State, prompted the Saudis to abandon the matter amid Arab anger over Israel’s offensive.

Trump wants Saudi Arabia to follow in the footsteps of countries including the United Arab Emirates, a Middle East trade and business hub, and Bahrain, which signed the Abraham Accords in 2020 and normalized ties with Israel.

Saudi Arabia establishing ties with Israel would be a grand prize for the Jewish State because the kingdom has huge influence in the Middle East and the wider Muslim world, and it is the world’s biggest oil exporter.

Reuters contributed to this report.

This post appeared first on FOX NEWS

Thailand cut electricity supplies on Wednesday to several areas in neighboring Myanmar that are home to sites at the center of a global, billion-dollar online scam industry.

As of Wednesday afternoon, at least one of the scam compounds was still operating, according to a local NGO in contact with workers inside one location. However, it’s unclear whether the cuts impacted other scam site operations in the area.

Online scam factories – many run by Chinese crime syndicates – have proliferated in Myanmar, which has been riven by a bloody civil war since the military seized power in 2021.

Often lured by the promise of well-paid jobs or other enticing opportunities, workers are routinely held against their will and forced to carry out online fraud schemes in heavily guarded compounds, where former detainees say beatings and torture are common.

On Wednesday, Thailand’s Interior Minister Anutin Charnvirakul toured a control station at the national electricity grid as staff pulled the plug on supplies to five locations across the border, in an event broadcast live on television.

Thailand “has stopped the electricity supply to Myanmar in five locations based on the decision of the National Security Council,” he told reporters.

“The electricity supply is not being stopped because the companies violated the contract, but because the electricity is being misused for scams, drugs and call centers,” he said.

One of those locations was in the town of Myawaddy, on the banks of a river that divides Thailand from Myanmar, and close to some of the largest scam compounds that NGOs say house thousands of workers. Several of the compounds lie near the border, where they can take advantage of more reliable electricity and telecoms services from Thailand.

Renewed focus on the sites came last month when a Chinese actor, having flown to Bangkok for what he thought was a movie casting call, was picked up at the airport and driven across the border into Myanmar and forced to work in a scam center there.

The scam compounds have operated for years, shielded by corruption and lawlessness that has long saturated Myanmar’s border regions — and only worsened after years of devastating civil war.

But Thailand has come under increased pressure to help curb the criminal activity and has held a series of high-profile meetings recently that suggest officials in Myanmar, Thailand and China may make stronger moves to crack down on the syndicates.

Thailand’s Prime Minister Paetongtarn Shinawatra is currently visiting Beijing, where she will meet Chinese leader Xi Jinping.

China’s Foreign Ministry said Wednesday that Beijing was “highly concerned” about recent incidents involving online scammers “at the Thailand-Myanmar border,” foreign ministry spokesperson Lin Jian said in a daily briefing.

Myawaddy alone is home to about 6,500 victims from 23 countries being held under duress in scam compounds, including about 4,500 Chinese nationals, according to an estimate from the Civil Society Network for Victim Assistance in Human Trafficking, a Thai NGO fighting against human trafficking.

Thailand has previously cut electricity supplies to scam sites near its border with Myanmar in recent years. However, it’s unclear if those prior cuts had any impact on operations.

In the event there were electricity cuts, compound bosses could switch to diesel-run generators for power, and Elon Musk’s Starlink – which is used elsewhere in Myanmar by various ethnic rebel groups – for internet connectivity.

‘Tonight you will see the lights’

Thailand’s cuts Wednesday also targeted Myanmar’s Three Pagodas Pass, which links southeastern Myanmar and western Thailand, prompting concerns among locals who worried how they would cope.

A resident of Thailand’s Mae Sot, which sits across the river from Myawaddy in Myanmar, said he doubted the power cuts would stop the scam centers.

“Tonight you will see the lights on in Shwe Kokko,” he said, referring to a notorious compound visible across the border.

The abduction of Chinese actor Wang Xing has brought renewed focus to the scams. Just days after he was reported missing in Mae Sot, Thai police said they located him in Myawaddy and brought him back to Thailand.

His subsequent safe return to China has spurred hundreds of Chinese families to call on their government to help to find and free their loved ones, who they believe are still trapped in the scam centers. Some have been missing for months or even years, their families say.

More than four years on from its coup, Myanmar’s military continues to fight multiple fronts across the country against powerful armed ethnic militias to hold onto power. More than 5,000 civilians have been killed and 3.3 million people displaced by the fighting, according to a United Nations report last September.

Amid the political turmoil, Myanmar has become a cyber scam hotspot, where fraud, cybercrime, human trafficking, money laundering and corruption have flourished, often with the tacit consent of the junta, experts say.

China previously worked with authorities in Myanmar to crack down on scam centers in northern Shan state, near the Chinese border. In 2023, as ethnic rebel groups gained ground against the junta, powerful warlord families – backed by the military to rule the region and oversee these fraud operations – were apprehended and handed to Chinese police.

Chinese authorities say more than 53,000 Chinese “suspects” – including trafficked victims – have been sent back to China from scam compounds in northern Myanmar.

But many scam centers have moved further south in Myanmar, including to Myawaddy, according to NGOs and experts who have long tracked these criminal operations.

This post appeared first on cnn.com

President Donald Trump and Israeli Prime Minister Benjamin Netanyahu addressed reporters at the White House Tuesday, during which the president laid out his plan for the US to “take over” Gaza, relocate Palestinians to neighboring countries, and redevelop the war-torn enclave into what he described as the “Riviera of the Middle East.”

Trump’s shocking comments break with decades of US foreign policy, which has long emphasized a two-state solution for Israel and Palestine, as well as the president’s past wariness over US intervention in the Middle East.

Here is what we know about Trump’s vision for Gaza – which is home to some two million Palestinians – including just how feasible such a proposal even is.

Trump said the US will ‘take over’ and ‘own’ Gaza long-term

“The US will take over the Gaza Strip and we will do a job with it too,” Trump said, unveiling what he called his “long-term ownership” and redevelopment plan for the enclave, much of which has been reduced to rubble after 15 months of war between Israel and Hamas.

Israeli airstrikes have damaged or destroyed around 60% of buildings, including schools and hospitals, and around 92% of homes, according to the United Nations.

“We’ll own it and be responsible for dismantling all of the dangerous unexploded bombs and other weapons on the site, level the site and get rid of the destroyed buildings,” Trump said Tuesday.

Trump did not rule out sending in US troops, saying “as far as Gaza is concerned, we’ll do what is necessary.”

It’s not clear how exactly Trump’s proposed land grab would work, and analysts have cast doubt on the feasibility of his plan.

Most of the two million people living in Gaza won’t want to leave, Sanner said, raising the question of whether they could be forcefully removed – which is prohibited under international law.

“That means that somebody, maybe the United States,” would have to step in – because “no Arab army is going to be carting people against their will out of their homeland,” Sanner said.

Trump’s vision for Gaza has no buy in from Palestinians

Trump’s plan flies in the face of the aspirations of Palestinians, who have long advocated for statehood and roundly dismissed Trump’s relocation proposal when he first floated it two weeks ago.

There are already about 5.9 million Palestinian refugees worldwide, most of them descendants of people who fled with the creation of Israel in 1948. Half of Gaza’s population were already refugees from outside the coastal strip. Approximately 90% of Gaza residents were displaced in the latest war, and many have been forced to move repeatedly, some more than 10 times, according to the UN.

Trump rejected the idea that displaced Palestinians would want to return to Gaza, describing it as a “symbol of death and destruction.”

“Why would they want to return? The place has been hell,” Trump said, ignoring a reporter who cried out: “Because it’s their home.”

Instead of Gaza, Trump suggested the Palestinians be provided a “good, fresh, beautiful piece of land” to live.

Tens of thousands of Palestinians walked for hours to return to their bombed-out homes in Gaza after a ceasefire came into force in late January.

A Hamas official called Trump’s plan a “recipe for creating chaos.”

“Our people in the Gaza Strip will not allow these plans to pass, and what is required is to end the occupation and aggression against our people, not expel them from their land,” spokesperson Sami Abu Zuhri said late Tuesday local time.

When asked whether he supports Israel’s claim to the occupied West Bank, which is home to more than three million Palestinians and coveted by far-right hardliners in Israel, Trump said “we haven’t taken a position on it yet” but said an announcement would be coming soon.

A shift would not be unprecedented. During his first term, Trump broke with decades of US foreign policy by recognizing Israeli sovereignty over the occupied Golan Heights. He also recognized Jerusalem as Israel’s capital, moving the US Embassy there.

Trump views Gaza as a real estate opportunity

The Israeli Palestinian conflict has been one of the Middle East’s most intractable problems. But Trump has portrayed it as a business opportunity.

The “potential in the Gaza Strip is unbelievable” and that it could become the “Riviera of the Middle East,” the real-estate investor turned president said.

“We have an opportunity to do something that could be phenomenal. And I don’t want to be cute, I don’t want to be a wise guy, but the Riviera of the Middle East, this could be something that could be so — this could be so magnificent,” Trump told reporters.

Asked who he envisions living in Gaza, Trump said, “I envision the world people living there. The world’s people. I think you’ll make that into an international, unbelievable place,” positing that some Palestinians might live there one day.

The president also said he plans to visit Gaza soon.

Last month, Trump praised Gaza as having a “phenomenal location, on the sea” and “the best weather,” echoing remarks made in 2024 by his son-in-law Jared Kushner, who called the waterfront property in Gaza “very valuable.”

Trump’s Special Envoy to the Middle East, Steve Witkoff, is also a real estate developer. Witkoff traveled to Gaza last week, becoming the first high-ranking US official known to visit the strip in years.

Trump’s proposal is welcome news for Israel’s far right

Israel’s far-right has long endorsed the idea of expelling Palestinians from Gaza and the West Bank, and lawmakers welcomed Trump’s comments about taking over the strip.

Jewish Power party leader Itamar Ben Gvir, who resigned as national security minister last month in protest over the Gaza ceasefire and hostage release deal, urged Netanyahu to adopt Trump’s plan in a statement to X Wednesday.

“Now it is clear: this is the only solution to the Gaza problem — this is the strategy for the ‘day after,’” he said.

While Israel’s government has previously rejected claims that it plans to force Palestinians out of Gaza, Netanyahu expressed support for Trump’s vision.

Pointing to Israel’s war objective of making sure Gaza does not pose a threat to it, Netanyahu said, “President Trump is taking it to a much higher level. He sees a different future for that piece of land that has been the focus of so much terrorism.”

The Israeli leader said Trump’s idea could “change history” and that it is “worthwhile really pursuing this avenue.”

Trump claimed his plan has broad support – but Arab nations say it’s a non-starter

Trump told reporters that “everybody (he’s) spoken to loves the idea of the United States owning that piece of land” and that he hoped Jordan and Egypt would take in forced out Palestinians.

But Arab nations have long rejected any forced displacement of Palestinians from Gaza, which critics have argued would amount to ethnic cleansing.

In a statement Wednesday following Trump and Netanyahu’s news conference, Saudi Arabia affirmed its “unwavering” support for a Palestinian state and demanded an end to Israeli occupation.

“Achieving lasting and just peace is impossible without the Palestinian people obtaining their legitimate rights in accordance with international resolutions, as has been previously clarified to both the former and current US administrations,” the Saudi Foreign Ministry said in a statement to social media.

Saudi Arabia, Jordan, Egypt and other Arab allies issued a statement last week reaffirming their long-held desire for a two-state solution and pledging their “continued full support for the steadfastness of the Palestinian people on their land.”

Lawmakers on both sides of the aisle aren’t thrilled with the idea – at least for now

Trump’s remarks drew criticism and skepticism from lawmakers, including some Republicans.

South Carolina Republican Sen. Lindsey Graham called it an “interesting proposal” but also “problematic.”

“We’ll see what our Arab friends say about that. I think most South Carolinians would probably not be excited about sending Americans to take over Gaza. I think that might be problematic. But I’ll keep an open mind,” he said.

North Carolina Republican Sen. Thom Tillis said that “there are probably a couple of kinks in that Slinky, but I’ll have to take a look at the statement.”

New Hampshire Sen. Jeanne Shaheen, the top Democratic on the Foreign Relations Committee, said the idea “fails to recognize the need to have a Palestinian state, and the fact that until we address the concerns of the Palestinians, there will continue to be conflict in the region.”

Sen. Chris Coons, another key Democratic member of the committee, said Trump’s plan is “between offensive and insane and dangerous and foolish.”

This post appeared first on cnn.com

Resources & Energy Group Limited (ASX: REZ) (REZ or the Company) is pleased to announce the successful completion of its first gold doré pour from the trial vat leach program at the East Menzies Gold Project, following the scheduled carbon strip on 1 February 2025 in Kalgoorlie.

HIGHLIGHTS

  • REZ successfully pours first gold doré from its maiden vat leach trial at the East Menzies Gold Project
  • Gold doré from this first pour has now been transported to the Perth Mint for refining and sale
  • The trial shows the effectiveness of vat leaching as a gold recovery method and provides confidence for further expansion
  • Onsite operators anticipate a regular gold pour cycle, with gold pours expected to occur approximately every three weeks moving forward, reinforcing the continuity of production at East Menzies
  • Demonstrating confidence in this process, REZ has already submitted a second mining application with DMIRS for an expanded vat leach operation, covering 8 new vats and up to 40,000 tonnes of material from the Maranoa deposit
  • This gold doré pour coincides with record-high gold prices, strengthening REZ’s potential for strong cash flow generation in the coming months

REZ Group Managing Director J. Daniel Moore said:

‘The first gold doré pour is a transformational moment for REZ, proving the effectiveness of our vat leach process and reinforcing our ability to generate near-term cash flow.

The trial has given us the confidence to move forward with an expanded mining and processing program at East Menzies, and we are already taking steps to scale up our operations. We are well-positioned for sustainable growth with strong gold prices and an optimised production model.’

COMMISSIONING OF A MINING & PROCESSING PROGRAM

  • With the successful output from the vat leach trial confirmed, REZ is now progressing with commissioning a structured mining and processing program at East Menzies.
  • To accelerate growth, the Company has submitted an application to the Western Australian Department of Mines, Industry Regulation and Safety (DMIRS) for an additional 8 vat leach dams, allowing for the processing of up to 40,000 tonnes of material from the Maranoa deposit.
  • This expansion positions REZ to transition from a trial phase to a structured, scalable gold recovery operation and gold producer.
STRATEGIX EXPANSION AND PRODUCTION GROWTH
  • Demonstrated Gold Recovery Success – The trial vat leach process has successfully recovered gold from the Maranoa deposit, validating this low-cost processing method.
  • Gold Doré Transported to Perth Mint – Gold doré bars from this first pour have now been delivered to the Perth Mint for refining and sale.
  • Scaling Up Operations – REZ’s new DMIRS application represents a significant step forward in unlocking the full production potential of the consolidated East Menzies Project.
  • Sustained Production Strategy – The Company is implementing a stockpiling and batch processing model, ensuring consistent production while maintaining flexibility in refining and sales.

EXPLORATION UPSIDE: GIGANTE GRANDE

Beyond near-term production, REZ’s Gigante Grande prospect presents a potential company-defining gold discovery. The Company continues to refine its exploration model and sees multi-million-ounce potential at this prospect.

Click here for the full ASX Release

This post appeared first on investingnews.com

As a new year began, the cannabis industry saw a range of impactful events in January.

Legal obstacles continued to impede progress on a once-promising attempt to reschedule cannabis in the US, and President Donald Trump’s leadership choices for key agencies are diminishing hopes it can be accomplished.

Meanwhile, cannabis banking reform won’t be discussed at Wednesday’s (February 5) meeting of the Standing Senate Committee on Banking, Commerce and the Economy, and Congress seems in no rush to address it.

Read on for more details on these events, which highlight the complex and dynamic nature of the cannabis industry as it continues to navigate legal, financial and regulatory challenges while experiencing growth and evolution.

US lawmakers unlikely to prioritize banking reform

The SAFER Banking Act was blocked from being attached to a government funding bill in December, delaying the issue until the next Congress session and delaying the prospects for cannabis banking reform.

With Republicans now holding a majority of the Senate, it appears unlikely that the issue will be raised at the next Senate banking committee meeting, which is scheduled for Wednesday and will focus on debanking.

At this point, the path forward for banking reform in the US is uncertain.

Senator Tim Scott, the Senate banking committee’s new chair, opposed the SAFER Banking Act during its last hearing in September 2023, citing concerns that the bill would facilitate money laundering and illegal trade of “weapons, fentanyl and even people.’ A new bill would likely need provisions to address those concerns in order to secure his vote.

New Senate Majority Leader John Thune (R-SD) has an even more contentious history with cannabis legislation. He opposed the SAFE Banking Act when House lawmakers tried to attach it to a stimulus relief bill in 2020, and he was also one of 26 lawmakers who urged US Attorney General Merrick Garland to reject the Department of Health and Human Services’ recommendation to reschedule cannabis under the Controlled Substances Act.

Despite rumors that lawmakers will soon reintroduce cannabis banking legislation, a spokesperson for Cannabis Caucus Co-chair Rep. Dave Joyce (R-OH) told Marijuana Moment on January 24 that a new bill is “not imminent.’

Cannabis rescheduling meets delays and controversies

In December, the push to reschedule cannabis hit legal and procedural hurdles. A hearing set for January 21 was ultimately canceled, with Chief Administrative Law Judge John Mulrooney, who is overseeing the process, criticizing the US Drug Enforcement Administration’s (DEA) for failing to submit required documents.

On January 7, Mulrooney, wrote to DEA Administrator Anne Milgram, informing her of his decision to grant a request to remove the agency from proceedings. The request was filed by cannabis advocacy groups on the grounds of improper conduct within the DEA “related to alleged improper ex parte communications between the Agency and other actors’ — specifically Smart Approaches to Marijuana, a prominent anti-cannabis legalization group.

Mulrooney gave the DEA until January 13 to file a response, but the hearing was ultimately canceled “pending resolution of an appeal filed by a party in the proceedings” on January 15.

Milgram announced her departure from the agency the next day.

Agency official George Papadopoulos stepped in as her replacement until Trump chose Derek Maltz, a retired director of special operations for the DEA, to lead the administration on January 21.

In a January 3 interview, Maltz told NTD’s Steve Lance that America’s cannabis industry an “open door” to the Chinese Communist Party’s cannabis-growing operations. He also suggested that cannabis with higher strains of THC leads to psychosis, depression and anxiety, and said that cannabis acts as a gateway drug, eventually leading young people to other drugs like Oxy or Xanax, which could end up being laced with fentanyl.

Further clouding the future of cannabis legalization, Pam Bondi, Trump’s nominee for attorney general, repeatedly refused to clarify her position on cannabis issues during a question-and-answer period following her confirmation hearing before the Senate Judiciary Committee. This was despite Trump’s previous indications of support for the issue, and his full pardon to Russ Ulbricht, operator of the dark web drug market Silk Road.

Amid the delay in the rescheduling processes, a new poll from NuggMD reveals that a whopping 96 percent of Americans don’t trust the DEA to serve as an “unbiased proponent” of cannabis rescheduling.

Virginia makes progress on adult-use cannabis

Lawmakers on a Virginia Senate committee have advanced Senate Bill 970, which proposes a framework to legalize and regulate an adult-use cannabis market in the state. If passed, cannabis retail licenses could be issued on September 1, 2025, with sales slated to begin by May 1, 2026.

The bill was introduced by Senator Aaron Rouse (D) on January 17. Despite a veto threat from Virginia Governor Glenn Youngkin (R), both the Senate and House committees in Virginia have advanced the proposed legislation in four separate voting rounds. It is now heading to Virginia’s House of Delegates.

Separately, Virginia’s House of Delegates advanced HB 2485 on Monday (February 3). It is similar to legislation penned by Delegate Paul Krizek (D), and would allow adults to purchase up to 2.5 ounces of cannabis from regulated state-licensed retailers. It is now on track for consideration in the Senate.

Tilray sees growth across all segments in quarterly results

Tilray Brands (NASDAQ:TLRY) reported financial results for its second fiscal quarter of 2025 on January 10, revealing a 9 percent increase in net revenue from Q2 2024 to US$211 million.

Growth across all four business segments — alcoholic beverages, cannabis, distribution and wellness — also resulted in a 29 percent increase in gross profit compared to the previous year, with US$61 million earned.

During its earnings presentation, Tilray introduced a new initiative called Project 420, a US$25 million synergy plan to optimize operations and cut costs for its beverage business, which earned US$63 million in net revenue and showed the strongest growth by percentage, advancing at an annual rate of 36 percent. Tilray’s cannabis business segment, by comparison, grew by 35 percent in Q2 compared to 31 percent in the prior year, bringing in US$66 million in revenue.

The company also reaffirmed its net revenue guidance for fiscal year 2025, projecting net revenue to fall somewhere between US$950 million and US$1 billion.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com